DMAE (Dimethylethanolamine)

The DMAE Paradox: From Prescription Drug to Skincare Secret

Dimethylethanolamine (DMAE) is one of the most fascinating and misunderstood compounds in the dietary supplement industry. Structurally, it is almost identical to choline—the essential nutrient responsible for liver health, muscle movement, and the synthesis of the "learning neurotransmitter," acetylcholine. Because of this structural similarity, DMAE was heralded in the mid-20th century as a revolutionary brain-boosting compound.

Today, DMAE occupies a strange space in the wellness world. It is widely sold as a nootropic for focus and memory, yet the strongest modern scientific evidence supports its use not in the brain, but on the skin. Understanding DMAE requires untangling decades of historical medical use, complex biochemistry, and modern clinical realities.

What is DMAE?

DMAE is a naturally occurring amino alcohol found in small amounts in the human brain and in higher concentrations in certain seafood, particularly anchovies, sardines, and salmon.

Biochemically, DMAE is a precursor to choline. The only difference between the two molecules is that choline has three methyl groups attached to its nitrogen atom, while DMAE has only two. This missing methyl group makes DMAE highly lipophilic (fat-soluble), allowing it to cross the blood-brain barrier with ease. For decades, scientists believed that once DMAE entered the brain, it was rapidly methylated into choline and subsequently converted into acetylcholine. However, modern research suggests the relationship between DMAE and brain choline is far more complicated, and potentially antagonistic.

The Rise and Fall of Deanol

To understand DMAE's reputation as a "smart drug," one must look back to the 1960s and 1970s. During this era, DMAE was approved and sold as a prescription pharmaceutical under the brand name Deanol.

Deanol was prescribed primarily for children with learning and behavioral problems—conditions that today would be classified as Attention Deficit Disorder (ADD) or Attention-Deficit/Hyperactivity Disorder (ADHD). Early clinical trials from the 1970s showed promising results, with some studies indicating that Deanol improved test scores and behavior in children. Because it was believed to increase acetylcholine, it was also tested as a treatment for Alzheimer's disease, tardive dyskinesia, and Huntington's chorea.

However, as clinical trial standards became more rigorous in the 1980s and 1990s, the evidence supporting Deanol began to crumble. Well-designed, double-blind, placebo-controlled studies yielded almost entirely negative results for Alzheimer's and movement disorders. Furthermore, the FDA concluded that the efficacy of Deanol for ADD/ADHD could not be definitively proven. Consequently, Deanol was removed from the pharmaceutical market. Today, DMAE is available exclusively as a dietary supplement, often marketed on the back of those outdated 1970s studies.

Cognitive Function and Nootropic Claims: The Reality

If you look at authoritative databases like Examine.com, you will notice that DMAE receives a "D" grade (Very Low Confidence) for cognitive function. Why is there such a disconnect between supplement marketing and scientific consensus?

The issue lies in the "Choline Controversy." While DMAE crosses the blood-brain barrier, it does not easily convert into acetylcholine. In fact, studies show that DMAE can act as a competitive inhibitor of choline transport. It binds to the same receptors and transporters as choline, effectively blocking free choline from entering the brain.

Instead of directly boosting acetylcholine, DMAE incorporates itself into cellular membranes. It forms a phospholipid called phosphatidyl-dimethylaminoethanol (PDME), which replaces phosphatidylcholine (PC) in neural cell walls. While this alters membrane fluidity and may have some long-term neurological effects, it does not provide the acute, reliable spike in acetylcholine that users get from modern nootropics like Alpha-GPC or CDP-Choline.

For healthy adults seeking a reliable "smart drug" for studying or intense focus, DMAE is generally considered inferior to dedicated choline donors.

The Skin Firming Phenomenon

Ironically, while the oral cognitive evidence for DMAE is weak, its topical evidence is surprisingly strong. Examine.com awards DMAE a "B" grade for improving skin quality when applied topically.

Dermatological studies, most notably by Grossman (2005), have demonstrated that applying a 3% DMAE gel to the face results in a visible mitigation of forehead lines, periorbital fine wrinkles (crow's feet), and an improvement in lip shape and fullness.

How does a brain supplement firm the skin? The mechanism is entirely distinct from its neurological effects. When applied to the epidermis, DMAE causes the skin cells (keratinocytes) to form intracellular vacuoles. This causes the cells to swell, increasing the volume of the skin layer and stretching it taut. This cellular swelling effectively "irons out" wrinkles. While highly effective for cosmetic purposes, users should be aware that this is a temporary structural swelling, not a permanent increase in collagen production.

Lucid Dreaming and Sleep Architecture

One of the most consistent anecdotal reports from DMAE users—which is supported by limited clinical observation—is its effect on sleep architecture. When taken in the afternoon or evening, DMAE frequently induces highly vivid, colorful, and sometimes lucid dreams.

Acetylcholine plays a critical role in regulating REM (Rapid Eye Movement) sleep, which is the phase of sleep where dreaming occurs. Even if DMAE does not directly convert to acetylcholine, its interaction with cholinergic pathways and membrane phospholipids appears to alter REM sleep intensity. For individuals interested in lucid dreaming or dream recall, DMAE remains a popular, albeit unpredictable, tool.

Critical Safety Warnings: Pregnancy and Beyond

While DMAE is generally well-tolerated by healthy adults at standard doses (100-200mg), it carries one of the most severe safety warnings in the supplement industry: Teratogenicity.

In animal models, DMAE has been proven to cause severe birth defects. Because embryonic development—specifically the closure of the neural tube—requires massive amounts of choline, any disruption to choline metabolism is catastrophic for a fetus. Because DMAE inhibits choline transport, maternal ingestion of DMAE can starve the developing embryo of the choline it needs, leading to neural tube defects. Women who are pregnant, nursing, or trying to conceive must strictly avoid DMAE.

Additionally, individuals with epilepsy or bipolar disorder should avoid DMAE. Cholinergic compounds can lower the seizure threshold in epileptics and may trigger mood destabilization in bipolar individuals. Common side effects in healthy users include tension headaches, muscle stiffness in the neck and jaw, and insomnia if taken too close to bedtime.

Dosage and Supplementation Strategies

In dietary supplements, DMAE is almost exclusively sold as DMAE Bitartrate. It is crucial to understand that DMAE bitartrate is only about 37% DMAE by weight. Therefore, a capsule containing 500mg of DMAE bitartrate yields approximately 185mg of actual DMAE.

The standard clinical dose for general supplementation is 100mg to 200mg of actual DMAE per day. While historical studies on cognitive decline used massive doses (up to 1,800mg or 2,000mg daily), these are not recommended due to a sharp increase in side effects like headaches and confusion.

In the modern sports nutrition and nootropic catalog, DMAE is often found in pre-workouts or focus formulas at doses ranging from 75mg to 750mg, with a median dose of 500mg (usually as bitartrate). If you choose to supplement with DMAE, it is best taken in the morning to avoid insomnia, unless specifically using it for dream enhancement.